Q3 2025 BioInvent International AB Earnings Call Transcript
Key Points
- BioInvent International AB (FRA:BIX0) has prioritized its resources on two lead programs, BI-1808 and BI-1206, which are now in advanced clinical studies (Phase 2).
- The company has initiated a Phase 2A trial for BI-1206 in advanced or metastatic non-small cell lung cancer and uveal melanoma, based on promising data from heavily pre-treated patients.
- BI-1808 has shown strong efficacy as a monotherapy in T-cell lymphomas, with 100% disease control in certain patient groups and a good safety profile.
- The company has secured collaboration agreements with major pharmaceutical companies like Merck and AstraZeneca, which could lead to potential partnerships.
- BioInvent International AB (FRA:BIX0) is financially stable, with liquid funds and current investments amounting to SEK690 million, providing financing into Q1 2027.
- Net sales decreased significantly in Q3 2025 compared to Q3 2024, primarily due to a reduction in antibiotic production for customers.
- Operating costs increased from SEK120 million in Q3 2024 to SEK137 million in Q3 2025, driven by higher costs in lead programs and personnel.
- The company reported a negative result of minus SEK129.2 million for Q3 2025 and minus SEK207.1 million for the January to September period.
- Some clinical programs, such as BI-1910 and BI-1607, have been paused, which may delay potential future developments in these areas.
- The company faces competition in the evolving non-Hodgkin’s lymphoma treatment landscape, which could impact the success of its BI-1206 program.
Yes, welcome everybody to our Q3 report presentation.
And as usual, Stefan and myself will go through, what has happened during that time period. Stefan will cover the financials. I will do the rest.
And without any further ado, I will start the presentation.
Our forward-looking statement, and I would like to start with a quick summary, what has happened, events in the third quarter as well as the events after the end of the period.
And obviously one very important, event during the third quarter was our, prioritization, in the portfolio to really focus on the two lead programs, all the resources doubling down on the two most advanced programs, BI-1808 and BI-1206, and I will come back to a little bit more details later.
And then the other thing was that, there was a change in the board. So Vincent Osippaul, who is with us, for many years stepped down for priority reasons. And, I think this is a very normal change. And as I said, he has been with us almost 10 years.
So then the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
